Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.22 USD | -2.34% | -2.53% | -18.35% |
Financials (USD)
Sales 2024 * | 27.6B | Sales 2025 * | 27.98B | Capitalization | 84.47B |
---|---|---|---|---|---|
Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.72 x |
Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.47 x |
P/E ratio 2024 * |
194
x | P/E ratio 2025 * |
13.1
x | Employees | 18,000 |
Yield 2024 * |
4.56% | Yield 2025 * |
4.79% | Free-Float | 99.89% |
Latest transcript on Gilead Sciences, Inc.
1 day | -1.00% | ||
1 week | -0.87% | ||
Current month | +3.17% | ||
1 month | +0.36% | ||
3 months | -8.54% | ||
6 months | -10.76% | ||
Current year | -16.96% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.99% | 254 M€ | +12.83% | - | |
8.10% | 0 M€ | 0.00% | - | |
8.06% | 0 M€ | 0.00% | - | |
5.23% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 66.14 | -2.46% | 2 714 653 |
24-05-22 | 67.8 | +0.76% | 6,227,702 |
24-05-21 | 67.29 | -0.90% | 5,701,228 |
24-05-20 | 67.9 | +0.27% | 4,719,854 |
24-05-17 | 67.72 | -0.21% | 3,579,110 |
Delayed Quote Nasdaq, May 23, 2024 at 10:11 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.96% | 84.47B | |
+38.11% | 723B | |
+34.52% | 595B | |
-2.79% | 369B | |
+20.65% | 332B | |
+2.33% | 282B | |
+17.28% | 244B | |
+9.63% | 208B | |
-4.50% | 205B | |
+0.17% | 168B |
- Stock Market
- Equities
- GILD Stock